Volume 4, Issue 1
Editorialp. 1-4
Concept, characteristics and implications of cluster randomization
Author(s): Monica Taljaard, Jeremy M Grimshaw
Editorialp. 5–7
Attention must be paid: adverse event reporting needs improvement
Author(s): Samuel J Kessler and Charles L Bennett
News and Viewsp. 9-12
Study results suggest increasing disclosure in industry-sponsored clinical studies
Commentaryp. 13-18
Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn
Author(s): Christian Burri
Review: Clinical Trail Outcomesp. 19-33
Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer
Author(s): Rowan T Chlebowski
Review: Clinical Trail Outcomesp. 35-43
Long-term extension trials to prove the efficacy and safety of bisphosphonates
Author(s): Paul D Miller
Review: Clinical Trail Outcomesp. 45-53
Eliglustat tartrate: an oral therapeutic option for Gaucher disease type 1
Author(s): Gregory M Pastores and Derralynn Hughes
Review: Clinical Trail Outcomesp. 55-61
Afatinib: rationale for use in non-small-cell lung cancer based on clinical trail data
Author(s): Allan V Espinosa and Leora Horn
Review: Clinical Trail Outcomesp. 63-75
Dalbavancin: re-enforcing the arsenal against Gram-positive bacteria causing skin and skin structure infections
Author(s): Konstantinos Z Vardakas & Matthew E Falagas
Clinical Trail Perspectivep. 77–86
Considerations in the design of clinical trials for multibacillary leprosy treatment
Author(s): Maria Lucia Fernandes Penna
Clinical Trail Perspectivep. 87–99
Inclusion of older people in interventional clinical trials
Author(s): Prabhath Fernando, Amit Arora, Peter Crome
